The EC has approved a simplified Pfizer-BioNTech COVID-19 vaccination schedule for children aged 6 months through 4 years, reducing the primary series from three doses to two while adopting a uniform 10-μg pediatric formulation.
By: Regulatory Desk
The European Commission (EC) has approved a revised marketing authorization for Pfizer-BioNTech’s COVID-19 vaccine, Comirnaty, reducing the primary vaccination series for children aged 6 months to 4 years from three doses to two. The decision simplifies pediatric immunization schedules across the European Union and follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
Uniform Pediatric Dosing
Under the revised authorization, children aged 6 months through 11 years will receive a standardized 10 μg dose. For infants and young children aged 6 months to 4 years, the primary vaccination schedule is reduced from three 3 μg doses to two 10 μg doses. For children aged 5 through 11 years, the recommendation remains a single 10 μg dose.
Safety and Benefit-Risk Profile
Regulators identified no new safety concerns and concluded that the vaccine’s favorable benefit-risk profile remains unchanged across pediatric age groups. Available clinical and safety data supported the revised dosing strategy, with expected immune protection maintained under the simplified schedule. Pfizer and BioNTech did not disclose new efficacy findings alongside the authorization.
European Authorization Scope
The updated authorization is valid across all 27 European Union Member States, as well as Iceland, Liechtenstein, and Norway. BioNTech continues to serve as the marketing authorization holder for Comirnaty and its adapted formulations throughout the region and several other major global markets.
Pediatric Vaccination Strategy
The streamlined dosing regimen carries operational benefits for families and healthcare systems. Reducing the number of doses required for the youngest children may improve vaccine uptake, reduce missed appointments, and simplify administration within national immunization programs. Harmonizing pediatric formulations across a broader age range also supports more efficient procurement, storage, and inventory management.
Clinical Role of Comirnaty
Comirnaty, developed jointly by Pfizer and BioNTech, uses messenger RNA technology to instruct cells to produce the SARS-CoV-2 spike protein and generate an immune response without exposure to live virus. Since its initial authorization, the vaccine has undergone multiple regulatory updates to address evolving variants and public health needs. The latest EU authorization reflects ongoing efforts to optimize long-term COVID-19 vaccination strategies for pediatric populations.
Reference
European Commission Authorizes Update to Pediatric Use of Pfizer and BioNTech COVID-19 Vaccine